Olivomycin

This classification denotes a dna minor groove binding agent and antineoplastic antibiotic with the molecular formula C58H84O26, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 44003517D1, chemically known as olivomycin d, 3(b)-o-(2,6-dideoxy-3-c-methyl-4-o-(2-methyl-1-oxopropyl)-alpha-l-arabino-hexopyranosyl)- but generally known as olivomycin, which bears US NIH Compound Identifier 122806. European Medicines Agency schedules Olivomycin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB03507MIG. The term OLIVOMYCIN is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 22, No. 10, 1968, List 8). OLIVOMYCIN is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule olivomycin under HS 29419000 and SITC 54139. As of Q4 2014, OLIVOMYCIN remains the US FDA Preferred Term for this commodity. Olivomycin bears US NLM identifiers UMLS ID C0028967 and NCI Concept Code C715. SMILES: O(C1CC(OC2CC(OC3C(CC4C(C3=O)C(O)C3C(C4)CC(OC4OC(C(OC(=O)C)C(OC5OC(C(OC)C(O)C5)C)C4)C)CC3O)C(OC)C(=O)C(O)C(O)C)OC(C2O)C)OC(C1O)C)C1OC(C(OC(=O)C(C)C)C(O)(C1)C)C.